The purpose of this study is to gain initial safety and efficacy data on the experimental
agent REN-1654 in patients with pain that radiates down the leg(s), and is typical of
sciatica (lumbosacral radiculopathy). These patients will usually have a herniated disc that
is causing compression on the nerves coming out of the spinal column.